

1 **Supplementary material**

2

3 **Table of Contents**

4

5 Supplementary material ..... 1

6 1 Targeted literature review ..... 2

7 1.1 OVID search..... 2

8 1.2 Additional search..... 2

9 1.3 Results..... 2

10 2 References ..... 3

11 3 Tables..... 3

12

13

## 14 1 Targeted literature review

15

16 The steps followed to conduct the targeted literature review (TLR), adhere to the guidelines published by the  
17 Cochrane Collaboration for systematic literature review (SLR)<sup>(1)</sup>. However, a reminder that a TLR tend to be  
18 more pragmatic than SLR. The TLR followed four core stages: a) Definition of the scope of search and  
19 agreement of search (Table 1; Table 2); b) Implementation of searches strategies and abstract review to inform  
20 included papers (Table 2; Figure 1); c) Selection of priority articles and desk search (sections 1.2, 1.3); d) Data  
21 extraction and reporting.

### 22 1.1 OVID search

23 The TLR was developed using the electronic literature databases through OVID. The OVID platform is a search  
24 platform that provides standardised access to a wide range of literature databases (all Medline (R), all Embase  
25 and all Evidence Based Medicine (EBM) review databases). The timeframe of the search was restricted to the  
26 last 10 years (2006-2016). The search strings and their relationships using Boolean terms define the searches  
27 for each area of evidence (disease, intervention, utility, economic, comorbidities and effects). Search strings  
28 were filtered in titles only and strategies were identical across the databases. A summary of the scope and  
29 search strategy is provided in Table 1 and Table 2.

### 30 1.2 Additional search

31 To complement the step described above, additional non-systematic searches was conducted: either by  
32 selecting specific studies referenced in the list of references of priority articles, either searching in database  
33 publications of International Society of Pharmacoeconomics and Outcomes Research (ISPOR US and EU) (note  
34 that last years are included in Medline and are as such covered) or in grey Google literature.

### 35 1.3 Results

36 Figure 1 depicts the flow of information through the different phases of the TLR and Table 3 list all the selected  
37 studies found and analysed in this TLR.

38 **2 References**

39 1. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated  
40 March 2011].The Cochrane Collaboration, 2011. [Internet]. The Cochrane Collaboration; 2011 [cited  
41 2018 Jun 25]. Available from: <http://handbook-5-1.cochrane.org/>

42

43 **3 Tables**

44

45 **Table 1: Scope of the search strategies**

| Name                      | Efficacy and effects  | Economic studies  | HRQoL (utility)  |
|---------------------------|---|---|--|
| <b>Databases</b>          | The OVID platform (which includes all Medline (R), all Embase and all Evidence Based Medicine (EBM) review databases  |   |  |
| <b>Patient population</b> | COPD patients<br>(either stable patients or hospitalized due to an exacerbation)  |   |  |
| <b>Intervention</b>       | Physical exercise/activity or pulmonary rehabilitation  |   |  |
| <b>Comparators</b>        | Sedentary life style, no pulmonary rehabilitation, natural course of COPD   |   |  |
| <b>Outcome measures</b>   | Spirometry, lung function capacity, exercise capacity, severity classification, survival and mortality  | Reported resource use and cost parameters, incremental cost-effectiveness ratio (ICER)  | Reported HRQoL scores, utility or dis(utility)   |
| <b>Study design</b>       | <ul style="list-style-type: none"> <li>• RCTs (all head-to-head or placebo controlled studies using single or combination therapies)</li> <li>• Non-RCTs: trials or observational studies where participants were assigned by investigators non-randomly to treatment group(s)</li> </ul>   | <ul style="list-style-type: none"> <li>• Costs studies</li> <li>• Resource use studies</li> <li>• Economic evaluations</li> </ul> | <ul style="list-style-type: none"> <li>• Utility and HRQoL studies</li> </ul> <p><b>OR</b></p> <ul style="list-style-type: none"> <li>• Economic evaluations using utility measures</li> </ul> |
| <b>Restrictions</b>       | <ul style="list-style-type: none"> <li>• Language: English and Spanish</li> <li>• Publication year: 2006-2016</li> <li>• No case reports study</li> <li>• Country: Any</li> </ul>   |   |  |
| <b>Inclusion</b>          | <ul style="list-style-type: none"> <li>• Providing quantitative impact of exercise</li> <li>• On key COPD outcomes: spirometry (e.g.: FEV1), exercise capacity (e.g. 6MWT, CPET, ESWT), muscle strength, dyspnea (MRC), mortality, QoL/PRO (SGRQ, EQ-5D, CRDQ) or COPD burden (hospitalization, costs, ICER)</li> </ul>                     |   |  |
| <b>Exclusion</b>          | <ul style="list-style-type: none"> <li>• Population: no COPD or specific subgroups of COPD patients (e.g. obesity)</li> <li>• Intervention: not related to exercise</li> <li>• Outcomes: qualitative, measured during the physical exercise</li> <li>• Design: general (non-systematic) review or study protocol without results</li> </ul> |   |  |


46 HRQoL - Health-related quality of life; RCT – Randomized control trial; ICER - Incremental cost-effectiveness ratio; COPD- Chronic  
47 Obstructive Pulmonary Disease; FEV1: forced expiratory volume in 1 second; 6MWT: 6-minute walking test; ICER: incremental cost-  
48 effectiveness ratio; MRC: Medical Research Council dyspnea scale; CPET- Cardio pulmonary exercise testing; ESWT- endurance shuttle  
49 walk test, QOL-Quality of Life; PRO - Patient-Reported Outcomes; SGRQ - St. George's Respiratory Questionnaire; EQ-5D- EuroQol five  
50 dimensions questionnaire; CRDQ - Chronic Respiratory Disease Questionnaire

51 **Table 2: Search terms and strategy**

| Index | Thematic group                   | Search words  | Number of hits (N) |
|-------|----------------------------------|---|--------------------|
| #     | <b>Disease</b>                   |   |                    |
| 1     |                                  | Chronic obstructive pulmonary disease OR COPD   | 79904              |
|       | <b>Intervention</b>              |   |                    |
| 2     |                                  | Physical activity OR exercise OR sport OR training<br>OR inactivity OR sedentary  |                    |
| 3     |                                  | <b>#1 and #2</b>  | 5954               |
| 4     |                                  | Rehabilitation  |                    |
| 5     |                                  | <b>(#3 or 4#)</b>   | <b>8032</b>        |
|       | <b>Utility</b>                   |   |                    |
| 6     |                                  | Quality of life OR Utility OR QoI   |                    |
| 7     |                                  | <b>#5 and #6</b>  | 374                |
| 8     |                                  | EQ-5D OR SF-36 OR SF-6D   |                    |
| 9     |                                  | <b>#5 and (#6 or #8)</b>  | 376                |
|       |                                  | Saint George Respiratory Questionnaire<br>Mahler's dyspnea index<br>London Chest Activity of Daily Living scale<br>Scales for quality of well-being |                    |
| 11    |                                  | 6 minute walking test   |                    |
| 12    |                                  | <b>#5 and (#11 or #9)</b>   | 383                |
| 13    |                                  | Health status or Health state   |                    |
| 14    |                                  | <b>#5 and (#13 or #12)</b>  | 454                |
|       | <b>Economic</b>                  |   |                    |
| 15    |                                  | Economic OR Cost OR Burden  |                    |
| 16    |                                  | <b>#5 and #15</b>   | 52                 |
| 17    |                                  | Hospitalization   |                    |
|       |                                  | <b>#5 and (#15 or #17)</b>  | 92                 |
|       | <b>Comorbidities and effects</b> |   |                    |
| 18    |                                  | Comorbidity   |                    |
| 19    |                                  | Cardiovascular disease  |                    |
| 20    |                                  | Diabetes  |                    |
| 21    |                                  | Heart failure   |                    |
| 22    |                                  | Hypertension  |                    |
| 23    |                                  | Obesity   |                    |
| 24    |                                  | <b>#5 and (#18 or #19 or #20 or #21 or #22 or #23)</b>  | 177                |
| 25    |                                  | Symptoms OR severity or GOLD or Global Initiative<br>for Chronic Obstructive Lung Disease OR<br>Progression OR Bronchodilation                      |                    |
| 26    |                                  | Lung function capacity  | 117                |
| 27    |                                  | <b>#5 and (#26 or # 25)</b>   | 250                |
| 28    |                                  | Survival OR Mortality   |                    |
| 29    |                                  | <b>#5 and # 28</b>  | 85                 |
|       |                                  | <i>Union of all searches</i>  | 680                |
|       |                                  | <i>Union of all searches after removing duplicates</i>  | 448                |
|       |                                  | <i>Limiting to 2006 – 2016</i>  | 340                |

52 First column presents the historical index in OVID for the conducted searches. In some cases, indexes reflect a combination of previous  
53 searches. Second and third columns represent the thematic group and related search strings, and the fourth column represent the total  
54 number of studies/hits found by OVID.

55 **Figure 1: Prisma diagram**



56

57 **Table 3: List of priority articles**

| #  | Study  |
|----|--|
| 1  | Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available from: <a href="http://goldcopd.org">http://goldcopd.org</a> .  |
| 2  | Ali MS, Talwar D, Jain SK. The effect of a short-term pulmonary rehabilitation on exercise capacity and quality of life in patients hospitalised with acute exacerbation of chronic obstructive pulmonary disease. <i>Indian J Chest Dis Allied Sci.</i> 2014;56(1):13-9.  |
| 3  | Atsou K., Crequit P, Chouaid C, Hejblum G. Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. <i>PLoS One.</i> 2016; 11(6): e0156514.  |
| 4  | Bratås O, Espnes GA, Rannestad T, Walstad R. Pulmonary rehabilitation reduces depression and enhances health-related quality of life in COPD patients--especially in patients with mild or moderate disease. <i>Chron Respir Dis.</i> 2010;7(4):229-37   |
| 5  | Briggs A, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van-Mölken MP, Lomas DA. Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Med Decis Making.</i> 2017;37(4):469-480. |
| 6  | Briggs A, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van-Mölken MP, Lomas DA. Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Med Decis Making.</i> 2016.               |
| 7  | Burns DK, Wilson EC, Browne P, Olive S, Clark A, Galey P, Dix E, Woodhouse H, Robinson S, Wilson A. The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial. <i>Appl Health Econ Health Policy.</i> 2016;14(1):105-15.             |
| 8  | Hailey D, Jacobs P, Stickland M, Chuck A, Marciniuk DD, Mayers I, Mierzwinsky-Urban M. Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease: Clinical, Economic, and Budget Impact Analysis [Technology report number 126]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010 (CADTH report)  |
| 9  | Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. <i>N Engl J Med</i> 2007;356:775–89. (TORCH)   |
| 10 | Corhay JL1, Louis R. The UPLIFT study (Understanding Potential Long-term Impacts on Function with Tiotropium). <i>Rev Med Liege.</i> 2009 Jan; 64(1):52-7.   |
| 11 | Da Silva GP, Morano MT, Cavalcante AG, De Andrade NM, Daher Ede F, Pereira ED. Exercise capacity impairment in COPD patients with comorbidities. <i>Rev Port Pneumol</i> (2006). 2015;21(5):233-8.(abstract)   |
| 12 | Dürr S., Zogg S., Miedinger D., Steveling E. H, Maier S. Leuppi J.D. Daily Physical Activity, Functional Capacity and Quality of Life in Patients with COPD. <i>COPD.</i> 2014;11(6):689-96..  |
| 13 | Enfield K, Gammon S, Floyd J, Falt C, Patrie J, Platts-Mills TA, Truwit JD, Shim YM. Six-minute walk distance in patients with severe end-stage COPD: association with survival after inpatient pulmonary rehabilitation. <i>J Cardiopulm Rehabil Prev.</i> 2010;30(3):195-202.  |
| 14 | Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, Aizpiri S, Aguirre U, Capelastegui A. Impact of changes in physical activity on health-related quality of life among patients with COPD. <i>Eur Respir J.</i> 2010;36(2):292-300.   |
| 15 | Esteban C, Arostegui I, Aburto M, Moraza J, Quintana JM, Aizpiri S, Basualdo LV, Capelastegui A. Influence of changes in physical activity on frequency of hospitalization in chronic obstructive pulmonary disease. <i>Respirology.</i> 2014;19(3):330-8  |
| 16 | Esteban C, Garcia-Gutierrez S, Legarreta MJ, Anton-Ladislao A, Gonzalez N, Lafuente I, Fernandez de Larrea N, Vidal S, Bare M, Quintana JM -COPD Group I. One-year Mortality in COPD After an Exacerbation: The Effect of Physical Activity Changes During the Event. <i>COPD.</i> 2016;13(6):718-725  |

|    |   |
|----|---|
| 17 | Exuzides A, Colby C, Briggs A, Lomas DA, Rutten van-Mölken M, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S. Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Med Decis Making</i> . 2017;37(4):453-468   |
| 18 | Foglio K, Bianchi L, Bruletti G, Porta R, Vitacca M, Balbi B, Ambrosino N. Seven-year time course of lung function, symptoms, health-related quality of life, and exercise tolerance in COPD patients undergoing pulmonary rehabilitation programs. <i>Respir Med</i> . 2007;101(9):1961-70. Epub 2007 May 24.  |
| 19 | Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. <i>Thorax</i> . 2006;61(9):772-8.  |
| 20 | Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Antó JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. <i>Am J Respir Crit Care Med</i> . 2007;175(5):458-63.  |
| 21 | Gillespie P, O'Shea E, Casey D, Murphy K, Devane D, Cooney A, Mee L, Kirwan C, McCarthy B, Newell J; PRINCE study team. The cost-effectiveness of a structured education pulmonary rehabilitation programme for chronic obstructive pulmonary disease in primary care: the PRINCE cluster randomised trial. <i>BMJ Open</i> . 2013;3(11):e003479.   |
| 22 | Hakamy A, Bolton CE, McKeever TM. The effect of pulmonary rehabilitation on mortality, balance, and risk of fall in stable patients with chronic obstructive pulmonary disease. <i>Chron Respir Dis</i> . 2017;14(1):54-62.   |
| 23 | Hoogendoorn M, Talitha L. Feenstra, Yumi Asukai, Andrew H. Briggs, Ryan N. Hansen, Reiner Leidl, Nancy Risebrough, Yevgeniy Samyshkin, Margarethe Wacker, Maureen P. Rutten-van Mólken. External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value In Health</i> ; 2017;20: 397-403   |
| 24 | Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value Health</i> 2013;16:231–50. |
| 25 | Incorvaia C, Russo A, Foresi A, Berra D, Elia R, Passalacqua G, Riario-Sforza GG, Ridolo E. Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: the FIRST study. <i>Eur J Phys Rehabil Med</i> . 2014;50(4):419-26.  |
| 26 | Jacobsen R, Frølich A, Godtfredsen NS. Impact of exercise capacity on dyspnea and health-related quality of life in patients with chronic obstructive pulmonary disease. <i>J Cardiopulm Rehabil Prev</i> . 2012;32(2):92-100.  |
| 27 | Kavoura P, Kostikas K, Tselebis A, Bratis D, Kosmas E, Alchanatis M, Koulouris NG, Bakakos P, Loukides S. Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in Patients With COPD. <i>J Cardiopulm Rehabil Prev</i> . 2016;36(1):62-7.  |
| 28 | López Varela MV, Anido T, Larrosa M. Estado funcional y supervivencia de los pacientes con EPOC tras rehabilitación respiratoria. <i>Arch Bronconeumol</i> . 2006;42(9):434-9   |
| 29 | McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. <i>Cochrane Database Syst Rev</i> 2015;2: CD003793.   |
| 30 | McNamara RJ, McKeough ZJ, McKenzie DK, Alison JA. Physical comorbidities affect physical activity in chronic obstructive pulmonary disease: a prospective cohort study. <i>Respirology</i> . 2014;19(6):866-72.   |
| 31 | Miravittles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. <i>Int J Chron Obstruct Pulmon Dis</i> . 2016;11:123-32.   |
| 32 | Moy ML, Gould MK2, Liu IA2, Lee JS2, Nguyen HQ. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. <i>ERJ Open Res</i> . 2016;2(1).  |
| 33 | Nakahara Y., Yasunaga H., Inokuchi H., Ogata N., Horiguchi H., Matsuda S., Fushimi K., Haga N. Mortality-Reducing Effect of Rehabilitation for COPD: Observational Propensity-Matched Cohort Study Using a Nationwide Database. <i>Respir Care</i> . 2016;61(11):1497-1504.   |

|    |   |
|----|---|
| 34 | Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. <i>Chest</i> . 2006;129(3):536-44.   |
| 35 | Puhan M.A.Scharplatz M.Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review. <i>Respir Res</i> . 2005; 6(1): 54.   |
| 36 | Punekar SY, Roberts G, Ismaila A, O’Leary M. Cost-effectiveness of umeclidinium/vilanterol combination therapy compared to tiotropium monotherapy among symptomatic patients with chronic obstructive pulmonary disease in the UK. <i>Cost Eff Resour Alloc</i> . 2015; 13: 22.           |
| 37 | Revitt O, Sewell L, Morgan MD, Steiner M, Singh S. Short outpatient pulmonary rehabilitation programme reduces readmission following a hospitalization for an exacerbation of chronic obstructive pulmonary disease. <i>Respirology</i> . 2013;18(7):1063-8                               |
| 38 | Ringbaek T, Martinez G, Brøndum E, Thøgersen J, Morgan M, Lange P. Shuttle walking test as predictor of survival in chronic obstructive pulmonary disease patients enrolled in a rehabilitation program. <i>J Cardiopulm Rehabil Prev</i> . 2010;30(6):409-14                             |
| 39 | Saraiva C, Abreu T, Neves D, Rodrigues F. Mortality Predictive Factors in Subjects With COPD After a Pulmonary Rehabilitation Program: A 3-Year Study. <i>Respir Care</i> . 2016;61(9):1179-85.   |
| 40 | Sylvia LG, Bernstein EE, Hubbard JL, Keating L, Anderson EJ. Practical guide to measuring physical activity. <i>J Acad Nutr Diet</i> . 2014;114(2):199-208.   |
| 41 | Schroff P, Hitchcock J, Schumann C, Wells JM, Dransfield MT, Bhatt SP. Pulmonary Rehabilitation Improves Outcomes in Chronic Obstructive Pulmonary Disease Independent of Disease Burden. <i>Ann Am Thorac Soc</i> . 2017;14(1):26-32.  |
| 42 | Sievi NA Senn O, Brack T, Brutsche MH, Frey M, Irani S, Leuppi JD, Thurnheer R, Franzen D, Kohler M, Clarenbach CF. Impact of comorbidities on physical activity in COPD. <i>Respirology</i> . 2015;20(3):413-8.  |
| 43 | Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs A, Rutten-van Molken M, Chambers M, Lomas DA. Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Med Decis Making</i> . 2017;37(4):440-452           |
| 44 | Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. <i>N Engl J Med</i> . 2008;359(15):1543-54.  |
| 45 | Tsung Yu, Gerben Ter Riet, Milo Puhan, Anja Frei. Physical activity and risk of comorbidities in patients with chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> 2016; 48: OA3046 (abstract)   |
| 46 | Vaes AW, Garcia-Aymerich J, Marott JL, Benet M., Groenen MT., Schnohr P., Franssen FM., Vestbo J., Wouters EF., Lange P., Spruit MA. Changes in physical activity and all-cause mortality in COPD. <i>Eur Respir J</i> . 2014;44(5):1199-209  |
| 47 | Vestbo J; TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. <i>Eur Respir J</i> . 2004 Aug;24(2):206-10.  |
| 48 | Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, Silverman EK, Tal-Singer R; ECLIPSE investigators. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). <i>Eur Respir J</i> . 2008;31(4):869-73. |
| 49 | Von Leupoldt A, Hahn E, Taube K, Schubert-Heukeshoven S, Magnussen H, Dahme B. Effects of 3-week outpatient pulmonary rehabilitation on exercise capacity, dyspnea, and quality of life in COPD. <i>Lung</i> . 2008;186(6):387-91.  |
| 50 | Waschki B, Kirsten A, Holz O, Müller KC, Meyer T, Watz H, Magnussen H. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. <i>Chest</i> . 2011; 140(2):331-42  |
| 51 | Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, Meyer T, Rabe KF, Magnussen H, Watz H. Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. <i>Am J Respir Crit Care Med</i> . 2015;192(3):295-306.                |
| 52 | Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. <i>Value Health</i> . 2003;6(1):9–17.                                     |



|    |   |
|----|---|
| 53 | Wu W, Liu X, Wang L, Wang Z, Hu J, Yan J. Effects of Tai Chi on exercise capacity and health-related quality of life in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Int J Chron Obstruct Pulmon Dis</i> . 2014;7(9): 1253-63.                          |
| 54 | Zafar Zafari, Stirling Bryan, Don D. Sin, Tania Conte, Rahman Khakban, Mohsen Sadatsafavi. A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. <i>Value Health</i> . 2017;20(1):152-16220 (2017) 152 – 162.   |
| 55 | Zanini A, Chetta A, Gumiero F, Della Patrona S, Casale S, Zampogna E, Aiello M, Spanevello A Six-minute walking distance improvement after pulmonary rehabilitation is associated with baseline lung function in complex COPD patients: a retrospective study. <i>Biomed Res Int</i> . 2013;2013: 483162. |
| 56 | Zwerink M, Effing T, Kerstjens HA, Van der Valk P, Brusse-Keizer M, Zielhuis G, van der Palen J. Cost-Effectiveness of a Community-Based Exercise Programme in COPD Self-Management. <i>COPD</i> . 2016;13(2):214-23.   |